



# Breast Cancer Factsheet: Insights & Key Developments

Key Insights on Breast Cancer Care and Infrastructure

## Core Pillars:

- 1. Infrastructure
- 2. Treatment Access, Research Funding and Awareness Campaigns
- 3. Survival Rates, Early Detection and Palliative Care
- 4. Utilization of Biomarkers
- 5. Clinical Guidelines
- 6. Reimbursement
- 7. Breast Cancer Screening

Breast cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.

This factsheet provides a comprehensive overview of key pillars shaping breast cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- Breast cancer incidence: 29.1% of all female cancers
- Incidence rate: 41.89 per 100,000 per year
- Total cases (2018-2022): ~368,050 reported cases
- Ethnic distribution: Limited data available; incidence varies among regions
- Lifetime risk in Brazil: 1 in 12 women
- Daily diagnoses (2018-2022): ~202 women per day
- Breast cancer deaths (2018-2022): ~11.8% of total cases
- 5-year survival rate: ~74.3% (varies by stage)
- Stage I diagnosis increase: 29% (2008-2012) → 51% (2018-2022)
- Young women cases: 10.2% under 40 years old
- Most affected age group: 40-69 years
- Mammogram detection: 38% via screening programs
- Screening participation (ages 50-69): Only 24%





- Major cities host advanced centers (e.g., INCA in Rio) with HER2/ER/PR testing.
- Active expansion of NGS and precision medicine platforms in select hospitals.

ОТ


## Weakness

- Diagnostic infrastructure in rural areas remains limited.
- Reimbursement and logistics issues hinder consistent test availability.

## Opportunity

- Scale up NGS and BRCA testing in regional hospitals.
- Strengthen regional laboratories and telepathology services.

- Persistent urban-rural disparities in access to molecular diagnostics.
- Slow integration of advanced diagnostics into public care pathways.



- 5. Advanced nationwide infrastructure, widespread availability in public and private sectors, integration with clinical practice.
- 4. Strong infrastructure in major hospitals and cancer centers, some regional disparities.
- 3. Moderate infrastructure, primarily in private settings or research institutions.
- 2. Limited infrastructure, available only in select centers or for high-cost private testing.
- 1. Minimal or no infrastructure, testing mostly unavailable or sent abroad.

Country Specialized Genetic & Molecu Centers Testing Infrastruct	
	Jaio
South Africa	
Kenya	
Nigeria	
Egypt	
Morocco	
Algeria	
Ethiopia	
India O	
Japan O	
South Korea O	
China	
Thailand O	
Singapore	
United Kingdom O	
Germany	
France	
Netherlands	
Sweden	
Italy O	
Spain	
Poland	
Mexico	
Brazil	
Argentina O	
Chile	
Colombia	
United States	
Canada	
Australia	
New Zealand	
Greece	
Rwanda	
Uganda	
Serbia O	
Saudi Arabia	
UAE	
Syria	
Indonesia O	
Vietnam	
Philippines O	
Russia	





Treatment Access, Research Funding and Awareness Campaigns

0

## Strengths

- Public and private hospitals in urban centers offer modern therapies.
- Research supported by CNPq and international collaborations.

## Weakness


- Delays and inequities in treatment access, especially in public sector.
- Awareness campaigns don't fully reach remote and underserved areas.

## erved areas.

## Opportunity

- Expand awareness efforts via digital platforms and NGOs like FEMAMA.
- Streamline referral systems and prioritize early treatment initiation.

- Geographic and socioeconomic inequalities risk widening.
- Bureaucratic delays may undermine impact of existing policies.



- 4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.
- 3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.
- 2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.
- 1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa	0	<u> </u>	0
Kenya			
Nigeria			
Egypt	0	0	<u> </u>
Morocco			<u> </u>
Algeria			
Ethiopia			
India	<u> </u>		<u> </u>
Japan			
South Korea			
China	<u> </u>		<u> </u>
Thailand	<u> </u>	<u> </u>	<u> </u>
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy	0	0	0
Spain	0	0	0
Poland	<u> </u>	<u> </u>	<u> </u>
Mexico	0	<u> </u>	<u> </u>
Brazil	<u> </u>	<u> </u>	<u> </u>
Argentina	0	<u> </u>	<u> </u>
Chile	0	<u> </u>	0
Colombia	0	0	0
United States			
Canada			
Australia	0	0	
New Zealand	0	0	0
Greece	0	0	<u> </u>
Rwanda			
Uganda			
Serbia	0	<u> </u>	<u> </u>
Saudi Arabia	0	0	0
UAE	0	0	0
Syria	0		
Indonesia	0	0	<u> </u>
Vietnam	<u> </u>	0	<u> </u>
Philippines	<u> </u>	0	<u> </u>
Russia	0		<u> </u>





Survival Rates, Early Detection and Palliative Care

## Strengths

- Stage I diagnoses increased significantly (29% → 51% over a decade).
- Palliative care services are expanding within major cancer centers.

## Weakness

- 66% of patients in public system are still diagnosed at advanced stages.
- Palliative care access remains inconsistent in rural areas.

### Threats

- Delays in diagnosis and treatment reduce survival prospects.
  - Inconsistent access threatens equity in end-of-life care.

# 5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.

- 4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.
- 3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.
- 2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.
- 1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

3			
ness			
atients in tem are still	1	5	

	_	_	
Opportunity			Thre

0

- Invest in communitybased detection and palliative care teams.
- Improve early detection through mobile and community screening units.







- HER2, ER, and PR testing standard in urban cancer centers.
- Biomarker-guided therapies available through SUS for eligible patients.

0

• BRCA testing access is limited and concentrated in private sector.

2.6


 Long turnaround times and cost barriers hinder timely testing.

## Opportunity


- Expand BRCA and molecular testing via public-private partnerships.
- Subsidize advanced diagnostics to increase nationwide equity.

- Low public system capacity may delay full integration of biomarkers.
- Diagnostic inequality could limit effectiveness of targeted therapies.

- decisions, with national coverage and reimbursement ensuring accessibility.
- 4. 61-80%. Biomarker testing is commonly used, but access may be limited in certain regions or patient groups. Some disparities exist in coverage or affordability, but it is still a crucial part of cancer diagnostics
- 3. 41-60% Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.
- 2. 20-40% Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.
- 1. <20% Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.











- National guidelines largely aligned with ESMO and NCCN standards.
- Major centers apply multidisciplinary, evidence-based approaches.

## S W

- O T


## Weakness

- Implementation is uneven, especially in resource-limited regions.
- Not all centers can regularly update or train on latest guidelines.

## Opportunity

- Create national digital platforms for guideline dissemination.
- Increase CME access and audit compliance across all regions.

- Resource and infrastructure gaps may block nationwide adoption.
- Guideline variability could lead to treatment inconsistencies.




	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	*	×	0	*	*
Feasibility of Integration	*	*	0	*	*
Adoption of International Guidelines	*	*	0	*	*
Engagement with Updates	*	*	*	0	*
ESMO Guidelines Implementation	*	*	•	*	*







- SUS covers standard surgery, chemotherapy, and trastuzumab.
- Legal frameworks support treatment access obligations.



## Weakness

- Delays exceeding 60 days to treatment initiation still common.
- CDK4/6 and PARP inhibitors often not covered or require appeals.

## Opportunity

- Update reimbursement lists to reflect current global best practices.
- Improve enforcement of legal care timelines under SUS.

- Resource constraints may slow inclusion of new therapies.
- Inconsistent reimbursement policies create care gaps between regions.



- Yes A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.
- Partial A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.
- No No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

South Africa	Country	Reimbursement	No-cost Access
Kenya	Courtery	Reimbursement	110 0031 /100033
Nigeria	South Africa	0	×
Egypt         O           Morocco         X           Algeria         X           Ethiopia         X           India         X           Japan         O           South Korea         O           China         O           China         O           China         O           China         O           China         O           Thailand         O           Singapore         O           United Kingdom         O           Germany         O           Germany         O           O         O           Prance         O           Netherlands         O           Sweden         O           O         O           Netherlands         O           Sweden         O           O         O           Spain         O           O         O           Italy         O           Spain         O           O         O           Poland         O           Mexico         O           Sprail         O	Kenya	×	×
Morocco         0         X           Algeria         0         X           Ethiopia         X         X           India         0         X           Japan         0         0           South Korea         0         0           China         0         0           Thailand         0         0           Singapore         0         0           United Kingdom         0         0           Germany         0         0           France         0         0           Netherlands         0         0           Sweden         0         0           Italy         0         0           Spain         0         0           Poland         0         0           Mexico         0         X           Brazil         0         X           Argentina         0         X           Chile         0         0           Colombia         0         X           United States         0         0           Canada         0         0           Quarda         X         X<	Nigeria	×	×
Algeria	Egypt	0	0
Ethiopia	Morocco	0	×
India	Algeria	0	×
Japan	Ethiopia	×	×
South Korea         O           China         O           Thailand         O           Singapore         O           United Kingdom         O           Germany         O           France         O           Netherlands         O           Sweden         O           Italy         O           Spain         O           Poland         O           Mexico         X           Brazil         O           Argentina         X           Chile         O           Colombia         X           United States         O           Canada         O           Australia         O           New Zealand         O           Greece         O           Rwanda         X           X         X           Uganda         X           Serbia         O           Saudi Arabia         O           Indonesia         O           Vietnam         X           X         X	India	0	×
China         0         0           Thailand         0         0           Singapore         0         0           United Kingdom         0         0           Germany         0         0           France         0         0           Netherlands         0         0           Sweden         0         0           Italy         0         0           Spain         0         0           Poland         0         0           Mexico         0         X           Brazil         0         X           Argentina         0         X           Chile         0         0           Colombia         0         X           United States         0         0           Canada         0         0           Australia         0         0           New Zealand         0         0           Greece         0         0           Rwanda         X         X           Uganda         X         X           Serbia         0         0           Saudi Arabia         0	Japan	0	0
Thailand Singapore O United Kingdom Germany France Netherlands Sweden O Italy Spain Poland Mexico Brazil Argentina Chile Colombia United States O Canada Australia New Zealand O Greece Rwanda Serbia Syria UAE Syria Indonesia Vietnam Philippines  O O O O O O O O O O O O O O O O O O	South Korea	0	0
Singapore         0           United Kingdom         0           Germany         0           France         0           Netherlands         0           Sweden         0           Italy         0           Spain         0           Poland         0           Mexico         0           Brazil         0           Argentina         0           Chile         0           Colombia         0           United States         0           Canada         0           Australia         0           New Zealand         0           Greece         0           Rwanda         X           Yearbia         0           Saudi Arabia         0           UAE         0           Syria         0           Indonesia         0           Vietnam         X           Philippines         X	China	0	0
United Kingdom         O         O           Germany         O         O           France         O         O           Netherlands         O         O           Sweden         O         O           Italy         O         O           Spain         O         O           Poland         O         O           Mexico         O         X           Brazil         O         X           Argentina         O         X           Chile         O         O           Colombia         O         X           United States         O         O           Canada         O         O           Australia         O         O           New Zealand         O         O           Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O	Thailand	0	0
Germany         0         0           France         0         0           Netherlands         0         0           Sweden         0         0           Italy         0         0           Spain         0         0           Poland         0         0           Mexico         0         X           Brazil         0         X           Argentina         0         X           Chile         0         0           Colombia         0         X           United States         0         0           Canada         0         X           United States         0         0           Canada         0         0           Australia         0         0           New Zealand         0         0           Greece         0         0           Rwanda         X         X           Uganda         X         X           Serbia         0         0           Saudi Arabia         0         0           UAE         0         0           Syria         0         0 <td>Singapore</td> <td>0</td> <td>0</td>	Singapore	0	0
France         O         O           Netherlands         O         O           Sweden         O         O           Italy         O         O           Spain         O         O           Poland         O         O           Poland         O         O           Mexico         X         X           Brazil         O         X           Argentina         O         X           Chile         O         O           Colombia         O         X           United States         O         O           Canada         O         O           Australia         O         O           New Zealand         O         O           Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X	United Kingdom	0	0
Netherlands         0         0           Sweden         0         0           Italy         0         0           Spain         0         0           Poland         0         0           Mexico         0         X           Brazil         0         X           Argentina         0         X           Chile         0         0           Colombia         0         X           United States         0         0           Canada         0         0           Australia         0         0           New Zealand         0         0           Greece         0         0           Rwanda         X         X           Uganda         X         X           Serbia         0         0           Saudi Arabia         0         0           UAE         0         0           Syria         0         0           Indonesia         0         0           Vietnam         X         X	Germany	0	0
Sweden         0           Italy         0           Spain         0           Poland         0           Mexico         0           Brazil         0           Argentina         0           Chile         0           Colombia         0           United States         0           Canada         0           Australia         0           New Zealand         0           Greece         0           Rwanda         X           Uganda         X           Serbia         0           Saudi Arabia         0           UAE         0           Syria         0           Indonesia         0           Vietnam         X           X         X	France	0	0
Italy	Netherlands	0	0
Spain         O           Poland         O           Mexico         X           Brazil         O           Argentina         O           Chile         O           Colombia         O           United States         O           Canada         O           Australia         O           New Zealand         O           Greece         O           Rwanda         X           Uganda         X           Serbia         O           Saudi Arabia         O           UAE         O           Syria         O           Indonesia         O           Vietnam         X           Philippines         X	Sweden	0	0
Poland         0           Mexico         0           Brazil         0           Argentina         0           Chile         0           Colombia         0           United States         0           Canada         0           Australia         0           New Zealand         0           Greece         0           Rwanda         X           Uganda         X           Serbia         0           Saudi Arabia         0           UAE         0           Syria         0           Indonesia         0           Vietnam         X           Philippines         X	Italy	0	0
Mexico         X           Brazil         X           Argentina         X           Chile         O           Colombia         X           United States         O           Canada         O           Australia         O           New Zealand         O           Greece         O           Rwanda         X           Uganda         X           Serbia         O           Saudi Arabia         O           UAE         O           Syria         O           Indonesia         O           Vietnam         X           Philippines         X	Spain	0	0
Brazil         O         X           Argentina         O         X           Chile         O         O           Colombia         O         X           United States         O         O           Canada         O         O           Australia         O         O           New Zealand         O         O           Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Poland	0	0
Argentina         O         X           Chile         O         O           Colombia         X         X           United States         O         O           Canada         O         O           Australia         O         O           New Zealand         O         O           Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Mexico	0	×
Chile         O         O           Colombia         X           United States         O         O           Canada         O         O           Australia         O         O           New Zealand         O         O           Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Brazil	0	×
Colombia         X           United States         O           Canada         O           Australia         O           New Zealand         O           Greece         O           Rwanda         X           Uganda         X           Serbia         O           Saudi Arabia         O           UAE         O           Syria         O           Indonesia         O           Vietnam         X           Philippines         X	Argentina	0	×
United States  Canada  Canada  Australia  New Zealand  Greece  Rwanda  Uganda  Serbia  Saudi Arabia  UAE  Syria  Indonesia  Vietnam  Philippines	Chile	0	0
Canada         O         O           Australia         O         O           New Zealand         O         O           Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Colombia	0	×
Australia  New Zealand  Greece  Rwanda  Uganda  Serbia  Serbia  O  Saudi Arabia  UAE  Syria  Indonesia  Vietnam  Philippines	United States	0	0
New Zealand         O         O           Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Canada	0	0
Greece         O         O           Rwanda         X         X           Uganda         X         X           Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Australia	0	0
Rwanda         X           Uganda         X           Serbia         O           Saudi Arabia         O           UAE         O           Syria         O           Indonesia         O           Vietnam         X           Philippines         X	New Zealand	0	0
Uganda         X           Serbia         O           Saudi Arabia         O           UAE         O           Syria         O           Indonesia         O           Vietnam         X           Philippines         X	Greece	0	0
Serbia         O         O           Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Rwanda	×	×
Saudi Arabia         O         O           UAE         O         O           Syria         O         O           Indonesia         O         O           Vietnam         X         X           Philippines         X         X	Uganda	×	×
UAE  Syria  Indonesia  Vietnam  Philippines  W  Syria  N  N  N  N  N  N  N  N  N  N  N  N  N	Serbia	0	0
Syria  Indonesia  Vietnam  Philippines  N  Syria  N  N  N  N  N  N  N  N  N  N  N  N  N	Saudi Arabia	0	0
Indonesia O C Vietnam X X Philippines X	UAE	0	0
Vietnam X X Philippines X	Syria	0	0
Philippines *	Indonesia	0	0
	Vietnam	×	×
Russia O	Philippines	×	×
	Russia	0	0





- National mammography program targets women aged 50-69.
- Screening policies aligned with WHO and international norms.

# s w

0

## Weakness

- Only 24% of eligible women participate; urban-rural gaps persist.
- Equipment shortages and long wait times limit program impact.

## Opportunity

- Boost mobile mammography deployment and rural outreach.
- Run sustained awareness and education campaigns.

- Without increased funding and staffing, participation may stagnate.
- Delayed screenings risk continued late-stage diagnoses.

Country	Breast Cancer Screening
United States	Biennial mammograms (50-74 years)
United Kingdom	Triennial mammograms (50-71 years)
Canada	Mammograms every 2-3 years (50-74 years)
Australia	Biennial mammograms (50-74 years)
Germany	Mammograms every 2 years (50-69 years)
France	Biennial mammograms (50-74 years)
Netherlands	Mammograms every 2 years (50-75 years)
Sweden	Mammograms every 18-24 months (40- 74 years)
Italy	Mammograms every 2 years (50-69 years)
Spain	Mammograms every 2 years (50-69 years)
Poland	Mammograms every 2 years (50-69 years)
Japan	Mammograms every 2 years (40+ years)
South Korea	Biennial mammograms (40+ years)
China	Regional mammogram programs (40-69 years)
India	Opportunistic screening
Singapore	Biennial mammograms (50-69 years)
Saudi Arabia	Opportunistic screening; regional programs for women aged 40+
UAE	Opportunistic screening; encouraged every 2 years for 40-69 years
Syria	No national program; limited local initiatives due to conflict

Country	Breast Cancer Screening
Thailand	Biennial mammograms (50-69 years)
South Africa	Opportunistic screening
Kenya	No national program
Nigeria	No national program
Egypt	National awareness campaigns
Morocco	National program for 45-69 years
Algeria	Planned national program (50-69 years)
Ethiopia	No national program
Mexico	Biennial mammograms (40-69 years)
Brazil	Biennial mammograms (50-69 years)
Argentina	Biennial mammograms (50-69 years)
Chile	Mammograms every 3 years (50-69 years)
Colombia	Biennial mammograms (50-69 years)
New Zealand	Biennial mammograms (45-69 years)
Greece	Biennial mammograms (50-69 years)
Rwanda	No national program
Uganda	No national program
Serbia	Biennial mammograms (50-69 years)
Indonesia	Opportunistic screening; no national mammography program
Vietnam	Regional mammography programs; pilot programs in urban areas (age 45-69)
Philippines	Opportunistic screening; mammography recommended every 2 years for women 50+
Russia	National program for biennial mammograms (50-69 years)